A novel Menin-MLL1 inhibitor, DS-1594a, prevents the progression of acute leukemia with rearranged MLL1 or mutated NPM1

被引：17

作者：

Numata, Masashi ^{[1
]}

Haginoya, Noriyasu ^{[2
]}

Shiroishi, Machiko ^{[1
]}

Hirata, Tsuyoshi ^{[2
]}

Sato-Otsubo, Aiko ^{[3
,4
]}

Yoshikawa, Kenji ^{[1
]}

Takata, Yoshimi ^{[1
]}

Nagase, Reina ^{[1
]}

Kashimoto, Yoshinori ^{[2
]}

Suzuki, Makoto ^{[2
]}

Schulte, Nina ^{[5
]}

Polier, Gernot ^{[5
]}

Kurimoto, Akiko ^{[1
]}

Tomoe, Yumiko ^{[1
]}

Toyota, Akiko ^{[1
]}

Yoneyama, Tomoko ^{[2
]}

Imai, Emi ^{[2
]}

Watanabe, Kenji ^{[1
]}

Hamada, Tomoaki ^{[1
]}

Kanada, Ryutaro ^{[1
]}

Watanabe, Jun ^{[1
]}

Kagoshima, Yoshiko ^{[1
]}

Tokumaru, Eri ^{[1
]}

Murata, Kenji ^{[1
]}

Baba, Takayuki ^{[1
]}

Shinozaki, Taeko ^{[1
]}

Ohtsuka, Masami ^{[1
]}

Goto, Koichi ^{[1
]}

Karibe, Tsuyoshi ^{[1
]}

Deguchi, Takao ^{[6
]}

Gocho, Yoshihiro ^{[6
]}

Yoshida, Masanori ^{[3
]}

Tomizawa, Daisuke ^{[6
]}

Kato, Motohiro ^{[3
,4
,6
]}

Tsutsumi, Shinji ^{[1
]}

Kitagawa, Mayumi ^{[1
]}

Abe, Yuki ^{[1
]}

机构：

[1] Daiichi Sankyo Co Ltd, Shinagawa R&D Ctr, 1-2-5 Hiromachi,Shinagawa Ku, Tokyo 1400005, Japan

[2] Daiichi Sankyo RD Novare Co Ltd, Tokyo, Japan

[3] Natl Res Inst Child Hlth & Dev, Dept Pediat Hematol & Oncol Res, Tokyo, Japan

[4] Univ Tokyo, Dept Pediat, Tokyo, Japan

[5] Daiichi Sankyo Europe GmbH, Munich, Germany

[6] Natl Ctr Child Hlth & Dev, Childrens Canc Ctr, Tokyo, Japan

来源：

CANCER CELL INTERNATIONAL | 2023年 / 23卷 / 01期

关键词：

Menin-MLL1; inhibitor; MLL1-r or NPM1c acute leukemia; Leukemia-initiating cells; STEM-CELLS; IDENTIFICATION; PROGENITOR; MODELS;

D O I：

10.1186/s12935-023-02877-y

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

BackgroundMixed lineage leukemia 1-rearranged (MLL1-r) acute leukemia patients respond poorly to currently available treatments and there is a need to develop more effective therapies directly disrupting the Menin-MLL1 complex. Small-molecule-mediated inhibition of the protein-protein interaction between Menin and MLL1 fusion proteins is a potential therapeutic strategy for patients with MLL1-r or mutated-nucleophosmin 1 (NPM1c) acute leukemia. In this study, we preclinically evaluated the new compound DS-1594a and its salts.MethodsWe evaluated the preclinical efficacy of DS-1594a as well as DS-1594a center dot HCl (the HCl salt of DS-1594a) and DS-1594a center dot succinate (the succinic acid salt of DS-1594a, DS-1594b) in vitro and in vivo using acute myeloid leukemia (AML)/acute lymphoblastic leukemia (ALL) models.ResultsOur results showed that MLL1-r or NPM1c human leukemic cell lines were selectively and highly sensitive to DS-1594a center dot HCl, with 50% growth inhibition values < 30 nM. Compared with cytrabine, the standard chemotherapy drug as AML therapy, both DS-1594a center dot HCl and DS-1594a center dot succinate mediated the eradication of potential leukemia-initiating cells by enhancing differentiation and reducing serial colony-forming potential in MLL1-r AML cells in vitro. The results were confirmed by flow cytometry, RNA sequencing, RT-qPCR and chromatin immunoprecipitation sequencing analyses. DS-1594a center dot HCl and DS-1594a center dot succinate exhibited significant antitumor efficacy and survival benefit in MOLM-13 cell and patient-derived xenograft models of MLL1-r or NPM1c acute leukemia in vivo.ConclusionWe have generated a novel, potent, orally available small-molecule inhibitor of the Menin-MLL1 interaction, DS-1594a. Our results suggest that DS-1594a has medicinal properties distinct from those of cytarabine and that DS-1594a has the potential to be a new anticancer therapy and support oral dosing regimen for clinical studies (NCT04752163).

引用

页数：16

共 41 条

[11] Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. [J].

Falini, B ;

Mecucci, C ;

Tiacci, E ;

Alcalay, M ;

Rosati, R ;

Pasqualucci, L ;

La Starza, R ;

Diverio, D ;

Colombo, E ;

Santucci, A ;

Bigerna, B ;

Pacini, R ;

Pucciarini, A ;

Liso, A ;

Vignetti, M ;

Fazi, P ;

Meani, N ;

Pettirossi, V ;

Saglio, G ;

Mandelli, F ;

Lo-Coco, F ;

Pelicci, P ;

Martelli, MF .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (03) :254-266

[12] Epigenetic therapies in acute myeloid leukemia: where to from here? [J].

Fennell, Katie A. ;

Bell, Charles C. ;

Dawson, Mark A. .

BLOOD, 2019, 134 (22) :1891-1901

[13] It's All About MEis: Menin-MLL Inhibition Eradicates NPM1-Mutated and MLL-Rearranged Acute Leukemias in Mice [J].

Gundry, Michael C. ;

Goodell, Margaret A. ;

Brunetti, Lorenzo .

CANCER CELL, 2020, 37 (03) :267-269

[14] Leukemic stem cells: identification and clinical application [J].

Hanekamp, Diana ;

Cloos, Jacqueline ;

Schuurhuis, Gerrit Jan .

INTERNATIONAL JOURNAL OF HEMATOLOGY, 2017, 105 (05) :549-557

[15] MLL: a histone methyltransferase disrupted in leukemia [J].

Hess, JL .

TRENDS IN MOLECULAR MEDICINE, 2004, 10 (10) :500-507

[16] The same pocket in menin binds both MLL and JUND but has opposite effects on transcription [J].

Huang, Jing ;

Gurung, Buddha ;

Wan, Bingbing ;

Matkar, Smita ;

Veniaminova, Natalia A. ;

Wan, Ke ;

Merchant, Juanita L. ;

Hua, Xianxin ;

Lei, Ming .

NATURE, 2012, 482 (7386) :542-U141

[17] Therapeutic implications of menin inhibition in acute leukemias [J].

Issa, Ghayas C. ;

Ravandi, Farhad ;

DiNardo, Courtney D. ;

Jabbour, Elias ;

Kantarjian, Hagop M. ;

Andreeff, Michael .

LEUKEMIA, 2021, 35 (09) :2482-2495

[18]

Jonas Brian A, 2017, Sci Transl Med, V9, DOI 10.1126/scitranslmed.aan8205

[19] Unique and independent roles for MLL in adult hematopoietic stem cells and progenitors [J].

Jude, Craig D. ;

Climer, Leslie ;

Xu, Diyong ;

Artinger, Erika ;

Fisher, Jill K. ;

Ernst, Patricia .

CELL STEM CELL, 2007, 1 (03) :324-337

[20] Rates and trends of childhood acute lymphoblastic leukaemia: an epidemiology study [J].

Kakaje, Ameer ;

Alhalabi, Mohammad Marwan ;

Ghareeb, Ayham ;

Karam, Bahjat ;

Mansour, Bassam ;

Zahra, Bayan ;

Hamdan, Othman .

SCIENTIFIC REPORTS, 2020, 10 (01)

← 1 2 3 4 5 →